Cipla, on Wednesday, announced the launch of generic drug Sofosbuvir for treating chronic Hepatitis C under the brand name Hepcvir.

“Following the non-exclusive licensing agreement signed with Gilead Sciences in September last to manufacture and market chronic Hepatitis C medicines, Cipla is now all set to make the drug Sofosbuvir available to Indian patients in a week’s time,” the company said in a statement.

“Cipla has always brought accessible and affordable medicines to fight against diseases like AIDS and Hepatitis B; hence, Cipla has made it a priority to bring Hepcvir to patients in India as well as the other developing nations,” Cipla Managing Director and Global CEO Subhanu Saxena said.